Rosalind Advisors Inc. Has $12.08 Million Position in CG Oncology, Inc. $CGON

Rosalind Advisors Inc. boosted its position in CG Oncology, Inc. (NASDAQ:CGON) by 55.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 300,000 shares of the company’s stock after buying an additional 107,026 shares during the quarter. CG Oncology makes up about 4.3% of Rosalind Advisors Inc.’s holdings, making the stock its 10th largest position. Rosalind Advisors Inc.’s holdings in CG Oncology were worth $12,084,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in shares of CG Oncology by 15.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after buying an additional 433 shares during the last quarter. CWM LLC increased its holdings in CG Oncology by 10.9% in the 3rd quarter. CWM LLC now owns 6,865 shares of the company’s stock worth $277,000 after acquiring an additional 672 shares during the last quarter. Strengthening Families & Communities LLC bought a new stake in CG Oncology in the 3rd quarter valued at about $40,000. Swiss National Bank raised its stake in CG Oncology by 1.5% in the 3rd quarter. Swiss National Bank now owns 81,300 shares of the company’s stock valued at $3,275,000 after acquiring an additional 1,200 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in CG Oncology by 10.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 12,879 shares of the company’s stock valued at $335,000 after purchasing an additional 1,232 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Stock Down 2.6%

Shares of CGON opened at $62.97 on Friday. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $64.67. The stock has a market cap of $5.32 billion, a PE ratio of -30.42 and a beta of 1.18. The business’s 50-day moving average price is $54.21 and its 200-day moving average price is $44.31.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million during the quarter. Analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 11,145 shares of the firm’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CGON has been the subject of a number of research reports. The Goldman Sachs Group reiterated a “buy” rating and set a $82.00 target price on shares of CG Oncology in a research report on Monday, January 12th. HC Wainwright upped their price target on shares of CG Oncology from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Wedbush started coverage on shares of CG Oncology in a research note on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, Morgan Stanley set a $93.00 target price on shares of CG Oncology in a report on Friday, January 9th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $69.00.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.